Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Genetic testing for lipid disorders can improve cardiovascular risk stratification in patients and their families, however it remains infrequently used in clinical practice. Perceived obstacles related to cost, insurance, and implementation of services may account for some of the limited use. Integration of a cardiogenomics team can streamline genetic testing, counseling, and insurance approval. In order to assess the utility and feasibility of genetic testing in clinical care, we conducted a retrospective chart review of 99 patients referred to our cardiogenomics team for lipid abnormalities and personal and/or family history of atherosclerotic cardiovascular disease from July 2018 to August 2022. Of the 18 patients with pathogenic variants, 50 % had a modification made to therapy and overall experienced greater reductions in LDL-C compared to those with negative results. Most patients did not require prior authorization and had genetic testing covered by insurance. Our study shows that access to genetic testing is feasible, warranting a renewed focus on implementation with further research to understand the clinical impact and socioeconomic barriers to such programs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319545 | PMC |
| http://dx.doi.org/10.1016/j.ajpc.2025.101066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Redefining agroecological zones in China to mitigate climate change impacts on maize production.
Mol Plant
September 2025
National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan 430070, China; Hubei Hongshan Laboratory, Wuhan 430070, China. Electronic address:
This study introduces Multi-Dimensional Environment (MDE) zoning to enhance maize resilience and improve stagnant yields in China amidst climate change. Utilizing comprehensive environmental and yield data, MDE zoning accurately identifies areas for targeted, climate-adaptive breeding. The tool provides a flexible framework for updates using annual variety testing and daily environmental data, optimizing production and resource allocation.
View Article and Find Full Text PDFPrimary hyperoxaluria type 1 - an unexpected diagnosis after kidney transplantation.
Kidney Blood Press Res
August 2025
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder caused by a deficiency of the hepatic peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), which catalyses the conversion of glyoxylate to glycine, resulting in increased oxalate production. The clinical consequences of the progressive build up of oxalates include nephrocalcinosis, nephrolithiasis, chronic kidney disease and ultimately renal failure with extra-renal involvement. The diagnosis of PH1 is challenging due to the non-specific nature of its symptoms and the need for costly genetic testing.
View Article and Find Full Text PDFEmployee perspectives on genetic testing in the workplace: Results from a national survey.
Public Health Genomics
August 2025
Introduction: Genetic testing for health-related purposes is now offered in some workplace wellness programs, with notable ethical, legal, and social implications. However, little is known about employee perspectives on workplace genetic testing (wGT).
Methods: We surveyed a large, diverse national sample of 2,000 employed adults (mean age=43 years; 51% female).
In-vivo evidence of synucleinopathy in parkinsonism due to VCP mutation.
J Neural Transm (Vienna)
September 2025
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 40139, Italy.
Multisystem proteinopathy 1 (MSP1) is a rare autosomal dominant disorder caused by mutations in the valosin-containing protein (VCP) gene typically presenting with inclusion body myopathy (IBM), Paget's disease of bone (PDB), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). Parkinsonism is a rare feature of MSP1, occurring in 3-4% of cases, with limited post-mortem evidence suggesting neuronal synucleinopathy. We report a case of VCP-related parkinsonism providing the first in vivo demonstration of phosphorylated alpha-synuclein deposition in skin biopsy, a highly sensitive and specific in vivo biomarker of synucleinopathy.
View Article and Find Full Text PDFMulti-class machine learning-based classification of SCID-related genetic variants.
Immunol Res
September 2025
Department of Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Türkiye.
Background: Variants of uncertain significance (VUS) represent a major diagnostic challenge in the interpretation of genetic testing results, particularly in the context of inborn errors of immunity such as severe combined immunodeficiency (SCID). The inconsistency among computational prediction tools often necessitates expensive and time-consuming wet-lab analyses.
Objective: This study aimed to develop disease-specific, multi-class machine learning models using in silico scores to classify SCID-associated genetic variants and improve the interpretation of VUS.